These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 22906921)

  • 1. Gene therapy for brain tumors: basic developments and clinical implementation.
    Assi H; Candolfi M; Baker G; Mineharu Y; Lowenstein PR; Castro MG
    Neurosci Lett; 2012 Oct; 527(2):71-7. PubMed ID: 22906921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.
    Mineharu Y; King GD; Muhammad AK; Bannykh S; Kroeger KM; Liu C; Lowenstein PR; Castro MG
    Clin Cancer Res; 2011 Jul; 17(14):4705-18. PubMed ID: 21632862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.
    Mineharu Y; Muhammad AK; Yagiz K; Candolfi M; Kroeger KM; Xiong W; Puntel M; Liu C; Levy E; Lugo C; Kocharian A; Allison JP; Curran MA; Lowenstein PR; Castro MG
    Neurotherapeutics; 2012 Oct; 9(4):827-43. PubMed ID: 22996231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMGB1 mediates endogenous TLR2 activation and brain tumor regression.
    Curtin JF; Liu N; Candolfi M; Xiong W; Assi H; Yagiz K; Edwards MR; Michelsen KS; Kroeger KM; Liu C; Muhammad AK; Clark MC; Arditi M; Comin-Anduix B; Ribas A; Lowenstein PR; Castro MG
    PLoS Med; 2009 Jan; 6(1):e10. PubMed ID: 19143470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.
    Ghulam Muhammad AK; Candolfi M; King GD; Yagiz K; Foulad D; Mineharu Y; Kroeger KM; Treuer KA; Nichols WS; Sanderson NS; Yang J; Khayznikov M; Van Rooijen N; Lowenstein PR; Castro MG
    Clin Cancer Res; 2009 Oct; 15(19):6113-27. PubMed ID: 19789315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.
    King GD; Muhammad AK; Larocque D; Kelson KR; Xiong W; Liu C; Sanderson NS; Kroeger KM; Castro MG; Lowenstein PR
    Mol Ther; 2011 Oct; 19(10):1793-801. PubMed ID: 21505426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.
    Curtin JF; King GD; Candolfi M; Greeno RB; Kroeger KM; Lowenstein PR; Castro MG
    Curr Top Med Chem; 2005; 5(12):1151-70. PubMed ID: 16248789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.
    Candolfi M; King GD; Yagiz K; Curtin JF; Mineharu Y; Muhammad AK; Foulad D; Kroeger KM; Barnett N; Josien R; Lowenstein PR; Castro MG
    Neoplasia; 2012 Aug; 14(8):757-70. PubMed ID: 22952428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.
    King GD; Muhammad AK; Curtin JF; Barcia C; Puntel M; Liu C; Honig SB; Candolfi M; Mondkar S; Lowenstein PR; Castro MG
    Neuro Oncol; 2008 Feb; 10(1):19-31. PubMed ID: 18079358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma.
    Puntel M; A K M GM; Farrokhi C; Vanderveen N; Paran C; Appelhans A; Kroeger KM; Salem A; Lacayo L; Pechnick RN; Kelson KR; Kaur S; Kennedy S; Palmer D; Ng P; Liu C; Krasinkiewicz J; Lowenstein PR; Castro MG
    Toxicol Appl Pharmacol; 2013 May; 268(3):318-30. PubMed ID: 23403069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.
    Muhammad AK; Puntel M; Candolfi M; Salem A; Yagiz K; Farrokhi C; Kroeger KM; Xiong W; Curtin JF; Liu C; Lawrence K; Bondale NS; Lerner J; Baker GJ; Foulad D; Pechnick RN; Palmer D; Ng P; Lowenstein PR; Castro MG
    Clin Pharmacol Ther; 2010 Aug; 88(2):204-13. PubMed ID: 20164833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.
    Candolfi M; Curtin JF; Yagiz K; Assi H; Wibowo MK; Alzadeh GE; Foulad D; Muhammad AK; Salehi S; Keech N; Puntel M; Liu C; Sanderson NR; Kroeger KM; Dunn R; Martins G; Lowenstein PR; Castro MG
    Neoplasia; 2011 Oct; 13(10):947-60. PubMed ID: 22028620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
    Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
    Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.
    Ali S; King GD; Curtin JF; Candolfi M; Xiong W; Liu C; Puntel M; Cheng Q; Prieto J; Ribas A; Kupiec-Weglinski J; van Rooijen N; Lassmann H; Lowenstein PR; Castro MG
    Cancer Res; 2005 Aug; 65(16):7194-204. PubMed ID: 16103070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.
    Candolfi M; Kroeger KM; Muhammad AK; Yagiz K; Farrokhi C; Pechnick RN; Lowenstein PR; Castro MG
    Curr Gene Ther; 2009 Oct; 9(5):409-21. PubMed ID: 19860655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.
    Curtin JF; Candolfi M; Fakhouri TM; Liu C; Alden A; Edwards M; Lowenstein PR; Castro MG
    PLoS One; 2008 Apr; 3(4):e1983. PubMed ID: 18431473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.
    VanderVeen N; Raja N; Yi E; Appelman H; Ng P; Palmer D; Zamler D; Dzaman M; Lowenstein PR; Castro MG
    Hum Gene Ther Methods; 2016 Jun; 27(3):98-111. PubMed ID: 27056322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenoviral vector-mediated gene therapy for gliomas: coming of age.
    Castro MG; Candolfi M; Wilson TJ; Calinescu A; Paran C; Kamran N; Koschmann C; Moreno-Ayala MA; Assi H; Lowenstein PR
    Expert Opin Biol Ther; 2014 Sep; 14(9):1241-57. PubMed ID: 24773178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.